enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Results of a Phase I clinical trial were reported in 2016. [6]In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.

3. Monomethyl auristatin E - Wikipedia

   en.wikipedia.org/wiki/Monomethyl_auristatin_E

   In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. [1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and ...

4. Tisotumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Tisotumab_vedotin

   Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .

5. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   LFA-1 : psoriasis (blocks T-cell migration) Efungumab [1] Mycograb: scFv: human: Hsp90: invasive Candida infection: Eldelumab [4] mab: human: CXCL10 (IP-10) Crohn's disease, ulcerative colitis: Elezanumab [22] mab: human: repulsive guidance molecule A (RGMA) spinal cord injury and multiple sclerosis Elgemtumab [25] mab: human: ERBB3 (HER3 ...

8. Depatuxizumab mafodotin - Wikipedia

   en.wikipedia.org/wiki/Depatuxizumab_mafodotin

   148 251.25 g·mol −1 Depatuxizumab mafodotin ( INN ; development code ABT-414 ) is an antibody-drug conjugate designed for the treatment of cancer. [ 1 ] [ 2 ] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

9. Naptumomab estafenatox - Wikipedia

   en.wikipedia.org/wiki/Naptumomab_estafenatox

   73 513.02 g·mol −1 N Y (what is this?) (verify) Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma [ 1 ] and renal cell carcinoma .